Summary of Significant Accounting Policies - Summary of Revenue by Category (Details) - USD ($) $ in Thousands		3 Months Ended
		Jun. 30, 2022		Jun. 30, 2021
Disaggregation Of Revenue [Line Items]
Revenue		$ 64,513		$ 59,239
PGS
Disaggregation Of Revenue [Line Items]
Revenue		44,175		47,850
PGS | Point in Time
Disaggregation Of Revenue [Line Items]
Revenue		39,691		45,023
PGS | Over Time
Disaggregation Of Revenue [Line Items]
Revenue		4,484		2,827
Telehealth
Disaggregation Of Revenue [Line Items]
Revenue		11,884	[1]
Telehealth | Point in Time
Disaggregation Of Revenue [Line Items]
Revenue		9,361	[1]
Telehealth | Over Time
Disaggregation Of Revenue [Line Items]
Revenue		2,523	[1]
Consumer services
Disaggregation Of Revenue [Line Items]
Revenue		56,059		47,850
Consumer services | Point in Time
Disaggregation Of Revenue [Line Items]
Revenue		49,052		45,023
Consumer services | Over Time
Disaggregation Of Revenue [Line Items]
Revenue		7,007		2,827
Research Services
Disaggregation Of Revenue [Line Items]
Revenue		8,454		11,389
Research Services | Point in Time
Disaggregation Of Revenue [Line Items]
Revenue
Research Services | Over Time
Disaggregation Of Revenue [Line Items]
Revenue		8,454		11,389
Service
Disaggregation Of Revenue [Line Items]
Revenue	[2]	64,513		59,239
Service | Point in Time
Disaggregation Of Revenue [Line Items]
Revenue	[2]	49,052		45,023
Service | Over Time
Disaggregation Of Revenue [Line Items]
Revenue	[2]	$ 15,461		$ 14,216
Product Concentration Risk [Member] | Revenue Benchmark [Member] | PGS
Disaggregation Of Revenue [Line Items]
Percentage of Revenue		68.00%		81.00%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | PGS | Point in Time
Disaggregation Of Revenue [Line Items]
Percentage of Revenue		61.00%		76.00%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | PGS | Over Time
Disaggregation Of Revenue [Line Items]
Percentage of Revenue		7.00%		5.00%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Telehealth
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	[1]	19.00%		0.00%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Telehealth | Point in Time
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	[1]	15.00%		0.00%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Telehealth | Over Time
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	[1]	4.00%		0.00%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Consumer services
Disaggregation Of Revenue [Line Items]
Percentage of Revenue		87.00%		81.00%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Consumer services | Point in Time
Disaggregation Of Revenue [Line Items]
Percentage of Revenue		76.00%		76.00%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Consumer services | Over Time
Disaggregation Of Revenue [Line Items]
Percentage of Revenue		11.00%		5.00%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Research Services
Disaggregation Of Revenue [Line Items]
Percentage of Revenue		13.00%		19.00%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Research Services | Point in Time
Disaggregation Of Revenue [Line Items]
Percentage of Revenue		0.00%		0.00%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Research Services | Over Time
Disaggregation Of Revenue [Line Items]
Percentage of Revenue		13.00%		19.00%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Service
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	[2]	100.00%		100.00%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Service | Point in Time
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	[2]	76.00%		76.00%
Product Concentration Risk [Member] | Revenue Benchmark [Member] | Service | Over Time
Disaggregation Of Revenue [Line Items]
Percentage of Revenue	[2]	24.00%		24.00%

[1] There was no telehealth revenue for the three months ended June 30, 2021, as the Lemonaid Acquisition closed in November 2021.

[2] There was no Therapeutics revenue for the three months ended June 30, 2022 and 2021.